MERZ-AESTHETICS
5.11.2020 09:32:12 CET | Business Wire | Press release
Merz Aesthetics, a global leader in medical aesthetics, today announced the presentation of data from its medical aesthetics portfolio at the 18th edition of the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place virtually as “AMWC Global 2020, The Virtual Edition”, to be held from Thursday, November 5 to Saturday, November 7, 2020. Merz Aesthetics is an elite sponsor of the global industry congress.
“We are proud to continue our commitment to the medical aesthetics industry by sponsoring this virtual meeting. We are looking forward to sharing data on the Merz Aesthetics portfolio, engage with our customers and partners and present Merz Aesthetics in a new innovative format. It’s time to think differently to keep the momentum of the industry,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics.
In addition to the presentations listed below, Merz Aesthetics is sponsoring two symposium events to be held over the course of the meeting and led by renowned medical aesthetic experts:
“The Skin You Are In – Collagen Expert Session” to be held on Friday, November 6, 15:15h – 16:15h CET. The session will include injection videos and insights from renowned international experts:
- Dr. Gabriela Casabona – Aesthetic Physician, Spain
- Dr. Jani van Loghem – Aesthetic Physician, The Netherlands
- Professor Yana A. Yutskovskaya – Dermatologist, Russia
“conFRONT every LINE! – Upper Face Rejuvenation” to be held on Saturday, November 7, 12:30h – 13:30h CET. The session will include injection videos and insights from renowned international experts:
- Dr. Tatjana Pavicic – Dermatologist, Germany
- Dr. Thomas Rappl – Dermatologist, Austria
Oral Presentations
Gabriela Casabona: ‘CaHA as a Biostimulator’ (Evolution of Regenerative Aesthetics Where are We Now Session); Thursday, November 5, 13:30-15:30h CET, AMWC Stream 2*
Dr. Carla Pecora: ‘Botulinum Toxin Injection: Customized Eyebrow Reshape and Positioning, with an Individualized Approach’ (Forehead Treatment and Importance of the Eyebrow Line Session); Thursday, November 5, 16:30-18:30h CET, AMWC Stream 1*
Dr. Daria Voropai: ‘Midface Dilemmas: How Individual Approaches Require a Multiple Tissue Plane Approach and How Ultrasound, Tactile Feedback, Visual Cues Help Us to Achieve This’ (Cheeks: Fillers, Threads of Both? Session); Friday, November 6, 16:30-18:30h CET, AMWC Stream 2 *
Dr. Kate Goldie: ‘Redefining the Art of the Lip’ (Lips and Perioral Rejuvenation Session); Saturday, November 7th, 14:00-16:00h CET, AMWC Stream 2 *
Virtual E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress.
Botulinum Toxin
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. Martina Kerscher, MD - Germany, Sabrina Fabi, MD – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, Dr. med – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
- Decreased Therapeutic Effect Over Time Amongst Botulinum Toxin Type A Agents. Rashid Kazerooni – Merz North America, USA.
- Neurotoxin Impurities: A Review of Threats to Efficacy. Je-Young Park, MD - USA, Owen Sunga, MD, MSc – Singapore, Rungsima Wanitphakdeedecha, MD, MA, MSc – Thailand, Jürgen Frevert, PhD - Germany.
Belotero®
- Safety of Cohesive Polydensified Matrix Cross-Linked Hyaluronic Acid Volumizing Gel in Temporal Hollows and Cheeks: A Prospective, Open-Label, Post-Market Study. Tatjana Pavicic, MD –Germany; Gerhard Sattler, MD – Germany, Welf Prager, MD – Germany, Tanja Fischer, MD PhD – Germany, Gerd Gauglitz, MD – Germany, Matthias Hofmann, PhD - Germany; Hanna Dersch – Germany; Shahbaz Riaz, PharmD – USA, Martina Kerscher, MD – Germany.
- Hydration Effect of a Revitalizing CPM® Cross-Linked Hyaluronic Acid Gel Containing Glycerol. Kay Marquardt, Sabine Falk, Matthias Hofmann, Jeannette Simon, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
Radiesse®
- CaHA microspheres remodel collagen networks leading to improved skin quality and reveal new treatment possibilities. Gabriela Casabona, MD – Spain, Bartosch Nowag, Daniela Schäfer, Davide Greco, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany
- Combination of Calcium Hydroxylapatite Diluted with Normal Saline and Microfocused Ultrasound with Visualization for Skin Tightening. Yana Alexandrovna Yutskovskaya, MD - Russia, Anna Daniilovna Sergeeva, MD – Russia, Evgeniya Altarovna Kogan, MD PhD – Russia.*
Ultherapy®
- Optimizing Patient Outcomes through a Customized Approach of Microfocused Ultrasound with Visualization Treatments: Consensus Guidelines from an Expert Panel. Sabrina G. Fabi, MD - USA, John Joseph, MD - USA, Julia Sevi, MD PhD - UK, Jeremy B. Green, MD - USA, Jennifer Deaver Peterson, MD – USA.
*Merz-supported Investigator Initiated Trial
About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
